Exhibit 10.1
CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT
     This CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT, dated as of June 25,
2008 is made between Robert Gipson (the “Purchaser”) and ALSERES
PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
RECITALS
     WHEREAS, the Company requires certain funds for the operation of its
business; and
     WHEREAS, the Purchaser is willing to provide the Company with up to
$5,000,000 through the purchase of the Convertible Note (defined below) on the
terms and conditions hereafter provided;
     NOW, THEREFORE, in order to induce the Purchaser to purchase the
Convertible Note and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, and intending to be legally bound,
the Purchaser and the Company hereby agree as follows:
     1. DEFINED TERMS. When used in this Agreement the following terms shall
have the following meanings (such meanings being equally applicable to both the
singular and plural forms of the terms defined):
     “Affiliates” shall mean any corporation, company, partnership, joint
venture and/or firm that controls, is controlled by, or is under common control
with the Company. For purposes of this definition, “control” shall mean (a) in
the case of corporate entities, direct or indirect ownership of at least fifty
percent (50%) of the stock or shares having the right to vote for the election
of directors and (b) in the case of non-corporate entities, direct or indirect
ownership of at least fifty percent (50%) of the equity interest with the power
to direct the management and policies of such non-corporate entities.
     “Agreement” means this Convertible Promissory Note Purchase Agreement, as
it may be amended or modified and in effect from time to time.
     “Closing” has the meaning set forth in Section 2.2 hereof.
     “Common Stock” means the common stock, $0.01 par value per share, of the
Company.
     “Convertible Note” shall have the meaning set forth in Section 2.1 hereof.
     “Electing Purchaser” shall have the meaning set forth in Section 4.2
hereof.
     “Event of Default” shall have the meaning set forth in Section 9 hereof.
     “Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

--------------------------------------------------------------------------------

 

     “First Commercial Sale” shall mean, with respect to each Molecular Imaging
Product, the first commercial sale in a country as part of a nationwide
introduction by the Company, its Affiliates or its or its Affiliates’ licensees
or sublicensees.
     “Highest Lawful Rate” means the maximum lawful interest rate, if any, that
at any time or from time to time may be contracted for, charged, or received
under the laws applicable to the Purchaser which are presently in effect or, to
the extent allowed by law, under such applicable laws which allow a higher
maximum nonusurious interest rate than applicable laws now allow.
     “Loan Documents” means collectively, this Agreement and the Convertible
Note.
     “Maturity Date” means the earliest to occur of (a) December 31, 2010 and
(b) the date on which the Purchaser declares an Event of Default to have
occurred.
     “Molecular Imaging Products” shall mean products approved for sale by the
appropriate U.S. and/or foreign regulatory body containing as the active
ingredient the Company’s radio-labeled molecular imaging agents, currently in
development or developed by the Company in the future, including, without
limitation, the ALTROPANE® and FLUORATEC molecular imaging agents, for the
diagnosis and monitoring of Parkinson’s Disease and Attention Deficit
Hyperactivity Disorder using SPECT or PET camera imaging techniques.
     “Net Sales” shall mean the gross amount received by the Company, its
Affiliates and/or its or its Affiliates’ licensees or sublicensees on sales or
other dispositions of Molecular Imaging Products to Third Parties (other than
licensees or sublicensees) in bonafide, arm’s-length transactions, less the
following deductions:
     (a) Trade, cash and/or quantity discounts actually allowed and taken
directly with respect to such sales, as reflected in the amount invoiced;
     (b) Tariffs, duties, excises, sales taxes or other taxes imposed upon and
paid directly by the Company with respect to the production, sale, delivery or
use of the Molecular Imaging Product (excluding national, state or local taxes
based on income), as reflected in the amount invoiced;
     (c) Amounts repaid or credited by reason of rejections, defects, recalls or
returns, or because of chargebacks, refunds, rebates, retroactive price
reductions or delayed ship orders;
     (d) Amounts credited for uncollectible amounts on previously sold products;
     (e) Freight, insurance and other transportation charges incurred in
shipping a Molecular Imaging Product to Third Parties, as reflected in the
amount invoiced;
     (f) Deduction of one percent (1%) for distribution and warehousing
expenses; and
     (g) Any other reduction or specifically identifiable amounts included in
the gross invoice that are creditable for reasons substantially equivalent to
those listed above.

2

--------------------------------------------------------------------------------

 

     Notwithstanding anything in this Agreement to the contrary, “Net Sales”
shall exclude any sales or other disposition of Molecular Imaging Products for
test marketing, clinical trial purposes or compassionate or similar use.
     Net Sales amounts shall be determined from the books and records of the
Company, its Affiliates and/or its or its Affiliates’ licensees or sublicensees,
maintained in accordance with generally accepted accounting principles,
consistently applied.
     Sales between or among the Company, its Affiliates or their respective
licensees and sublicensees shall be disregarded for purposes of calculating Net
Sales. In the case of any sale or other disposal of a Molecular Imaging Product
between or among the Company and its Affiliates, licensees and sublicensees, for
resale, Net Sales shall be calculated as above only on the value charged or
invoiced on the first arm’s-length sale thereafter to a Third Party.
     In the case of any sale or other disposal for value, such as barter or
counter-trade, of any Molecular Imaging Product, or part thereof, other than in
an arm’s-length transaction exclusively for money, Net Sales shall be calculated
as above on the value of the non-cash consideration received or the fair market
price (if higher) of the Molecular Imaging Product in the country of sale or
disposal.
     In the event the Molecular Imaging Product is sold in a finished dosage
form in combination with one or more other active ingredients (a “Combination
Product”), the Net Sales of the Molecular Imaging Product, for the purposes of
determining royalty payments, shall be determined by multiplying the Net Sales
(as defined above) of the Combination Product by the fraction, ‘A/(A+B)’ where
‘A’ is the weighted (by sales volume) average sale price in the relevant country
of the Molecular Imaging Product when sold separately in finished form and ‘B’
is the weighted average sale price in that country of the other product(s) sold
separately in finished form. In the event that such average sale price cannot be
determined for both the Molecular Imaging Product and the other product(s) in
the Combination Product, Net Sales for purposes of determining royalty payments
shall be agreed by the Parties based on the relative value contributed by each
component, such agreement not to be unreasonably withheld.
     “Obligations” means all unpaid principal of and accrued and unpaid interest
on the Convertible Note, and all other obligations, interest, fees, charges and
expenses of the Company to the Purchaser arising under the Loan Documents.
     “Pre-Commercial Income” shall mean, with respect to each Molecular Imaging
Product, all license fees, milestone payments and other amounts received by the
Company and/or its Affiliates from Third Parties in connection with or related
to the licensing or sublicensing to such Third Parties of the Company’s and/or
its Affiliate’s rights under the intellectual property covering the Molecular
Imaging Product. Notwithstanding anything in the foregoing to the contrary,
“Pre-Commercial Income” shall exclude (a) any royalty payments or milestone
payments based upon commercial sales levels, (b) amounts received for research
and development activities undertaken for, or in collaboration with, such Third
Parties, (c) amounts received for debt or equity securities of the Company
and/or its Affiliates, provided that any amounts received in excess of the then
current fair market value of such debt or equity securities

3

--------------------------------------------------------------------------------

 

shall, to the extent of such excess, be deemed to be Pre-Commercial Income, and
(d) transfer pricing amounts paid in respect of Molecular Imaging Products
supplied to such Third Parties.
     “Purchaser” shall have the meaning set forth in the preamble to this
Agreement.
     “Securities Act” means the Securities Act of 1933, as amended.
     “Stockholder Approval” shall have the meaning set forth in Section 4.1(b)
hereof.
     “Third Party” shall mean any person or entity other than the Company or any
of its Affiliates.
     “Total Converted Balance” shall have the meaning set forth in Section 4.2
hereof.
     “Valid Claim” means a claim of any issued, unexpired United States or
foreign patent, which shall not be disclaimed, nor held invalid or unenforceable
by a court of competent jurisdiction in an unappealed or unappealable decision.
     2. CONVERTIBLE NOTE FACILITY.
          2.1 Purchase and Sale of the Convertible Note. At the Closing (as
defined below), the Purchaser agrees on the terms of and subject to the
conditions specified in this Agreement, to purchase from the Company, and the
Company agrees to sell to the Purchaser, a convertible promissory note dated as
of the date of the Closing in the form attached to this Agreement as Exhibit A
(the “Convertible Note”); provided, however, that in no event shall the
Purchaser be obligated hereunder to purchase, in the aggregate, more than a
principal amount of $5 million in Convertible Notes.
          2.2 Closing. The closing of the issuance and sale of the Convertible
Note issued hereunder shall be held at the offices of counsel to the Company at
5:00 p.m. on the date and place as the Company and the Purchaser mutually agree
in writing (such date, a “Closing”).
          2.3 Payment of Convertible Note Purchase Price. At the Closing,
(i) the Company shall deliver to the Purchaser a Convertible Note, and (ii) as
payment in full for the Convertible Note being purchased by the Purchaser at the
Closing, the Purchaser shall pay its purchase amount to the Company by wire
transfer of immediately available funds to an account designated by the Company.
          2.4 Interest. Interest shall accrue on the Convertible Note from the
date of issuance until the Convertible Note is paid in full or otherwise
converted pursuant to Section 4 hereof. The Company promises to pay interest on
the outstanding principal amount of the Convertible Note (i) until the Maturity
Date, or if earlier, conversion pursuant to Section 4 hereof, at a per annum
interest rate equal to five percent (5%), (ii) from and after the Maturity Date,
or during the continuance of an Event of Default, at a per annum rate equal to
ten percent (10%) or (iii) if less than the rates applicable under both clauses
(i) and (ii), the Highest Lawful Rate. Interest shall be calculated on the basis
of a 360-day year for the actual number of days elapsed. Interest shall accrue
until paid in full and all unpaid interest shall be due and payable on the
Maturity Date, unless otherwise converted pursuant to Section 4 hereof.

4

--------------------------------------------------------------------------------

 

          2.5 Method of Payment. All payments of principal, interest, and fees
hereunder shall be made on the date when due in immediately available funds in
United States Dollars to the Purchaser at his address specified on the signature
page hereof, or at such other address as shall be directed by the applicable
Purchaser in a writing received by the Company.
          2.6 Prepayments. The Company may not prepay any amounts under the
Convertible Note whether principal or interest.
          2.7 Usury Savings Clause. Notwithstanding any other provision herein,
the aggregate interest rate charged with respect to any of the Obligations,
shall not exceed the Highest Lawful Rate. If the rate of interest (determined
without regard to the preceding sentence) under this Agreement at any time
exceeds the Highest Lawful Rate, the outstanding amount under the Convertible
Note issued hereunder shall bear interest at the Highest Lawful Rate until the
total amount of interest due hereunder equals the amount of interest which would
have been due hereunder if the stated rates of interest set forth in this
Agreement had at all times been in effect. In addition, if when the Convertible
Note issued hereunder is repaid in full the total interest due hereunder is less
than the total amount of interest which would have been due hereunder if the
stated rates of interest set forth in this Agreement had at all times been in
effect, then to the extent permitted by law, the Company shall pay to the
Purchaser an amount equal to the difference between the amount of interest paid
and the amount of interest which would have been paid if the Highest Lawful Rate
had at all times been in effect. Notwithstanding the foregoing, it is the
intention of the Purchaser and the Company to conform strictly to any applicable
usury laws. Accordingly, if the Purchaser contracts for, charges, or receives
any consideration which constitutes interest in excess of the Highest Lawful
Rate, then any such excess shall be cancelled automatically and, if previously
paid, shall be applied to the outstanding principal amount of the Convertible
Note issued hereunder or be refunded to the Company.
     3. CONDITIONS PRECEDENT. The obligations of the Purchaser to purchase the
Convertible Note shall be subject to the following conditions precedent that on
the date of the Closing:
          3.1 Each of the representations and warranties of the Company
contained in this Agreement and the Convertible Note shall be true and correct
in all material respects; and
          3.2 At the time of, and immediately after giving effect to, the
issuance of the Convertible Note, no Event of Default shall have occurred and be
continuing.
     4. OPTIONAL CONVERSION.
          4.1 Conversion to Equity.
               (a) At any time during which the Convertible Note remains
outstanding, up to all of the outstanding principal and accrued interest under
the Convertible Note then outstanding may be converted, at the sole option of
the holder thereof and by written notice to the Company, into shares of Common
Stock of the Company at a conversion price equal to $2.50 per share.

5

--------------------------------------------------------------------------------

 

               (b) Notwithstanding anything to the contrary contained herein,
the Purchaser shall be prohibited from effecting a conversion pursuant to this
Section 4.1 if at the time of such conversion (i) the Common Stock issuable to
the Purchaser pursuant to such conversion or as a result of such conversion,
when taken together with all shares of Common Stock then held or otherwise
beneficially owned by the Purchaser exceeds 19.9% of the total number of issued
and outstanding shares of Common Stock of the Company immediately prior to such
conversion, (ii) the Common Stock issuable to the Purchaser pursuant to such
conversion or as a result of such conversion, exceeds 19.9% of the total number
of issued and outstanding shares of Common Stock of the Company immediately
prior to such conversion, in each case unless the stockholders of the Company
have approved the conversion of all of the shares of Common Stock issuable
hereunder and the transactions contemplated hereby pursuant to Nasdaq
Marketplace Rule 4350(i)(l)(D)(ii) and any other applicable rules and
regulations (“Stockholder Approval”). The foregoing provision however shall not
restrict the number of shares of Common Stock which the Purchaser may receive or
beneficially own in order to determine the amount of securities or other
consideration that the Purchaser may receive in the event of a merger, sale or
other business combination involving the Company.
               (c) The Company hereby covenants and agrees that in the event the
Purchaser is prohibited from effecting a conversion of the Convertible Note
pursuant to this Section 4.1, then upon receipt of written notice of such event
from the Purchaser, the Company shall use its best efforts to seek Stockholder
Approval.
          4.2 Conversion to Royalty Stream.
               (a) At any time the Purchaser may elect (as such, the “Electing
Purchaser”), at his sole option and by written notice to the Company, to
convert, in $1 million increments, up to the entire amount of the principal and
accrued interest then outstanding on the Convertible Note then held by the
Electing Purchaser (the “Total Converted Balance”), into the right to receive
from the Company the following payments related to the Company’s Molecular
Imaging Products:
                    (i) For each One Million ($1,000,000) of Total Converted
Balance,
                         (A) 2% of Pre-Commercial Income; plus
                         (B) a royalty at a rate of one half of one percent
(0.5%) of Net Sales of Molecular Imaging Products.
               By way of example only, if the Total Converted Balance being
converted by the Electing Purchaser is $3.5 million, the Company would be
required to pay 7% of Pre-Commercial Income (2% x 3.5) to the Electing Purchaser
plus a royalty of 1.75% on Net Sales of Molecular Imaging Products (0.5% x 3.5).
                    (ii) The Company agrees to provide the Purchaser with at
least 30 days prior written notice of the execution of a partnership agreement
for the Molecular Imaging products to enable them to make an election to convert
under this Section 4.2. Upon receipt of such notice, the Purchaser will have
30 days to elect such conversion. For purposes of

6

--------------------------------------------------------------------------------

 

clarity, any amounts which may be owed by the Company under Section 4.2(a)(i)
above after proper notice is given and no election is made, shall be owed on a
going-forward basis and shall not apply retroactively to any Pre-Commercial
Income received by the Company and/or its Affiliates or Net Sales of Molecular
Imaging Products prior to the date of such election to convert.
               (b) The Company shall make the payments set forth in
Section 4.2(a)(i) above on a calendar quarterly basis to the Electing Purchaser.
               (c) The Company shall deliver to the Electing Purchaser within
sixty (60) days after the end of each calendar quarter following the Electing
Purchaser’s election to convert, reasonably detailed written accountings of
Pre-Commercial Income and Net Sales of Molecular Imaging Products that are
subject to payments due to the Electing Purchaser hereunder for such calendar
quarter. When the Company delivers such accountings to the Electing Purchaser,
the Company shall also deliver all payments due under Section 4.2(a)(i) for such
calendar quarter.
               (d) On a country-by-country and Molecular Imaging
Product-by-Molecular Imaging Product basis, the royalty obligation of the
Company hereunder shall cease at the expiration of the last-to-expire Valid
Claim covering a Molecular Imaging Product in said country or, in the case of
countries where no Valid Claims covering a Molecular Imaging Product have been
granted, ten (10) years after the First Commercial Sale of a Molecular Imaging
Product in said country. In no event will the Company’s royalty obligation
hereunder cease so long as royalties in excess of those owed hereunder are paid
to the Company by its licensee of any or all of the Molecular Imaging Products.
     5. REPRESENTATIONS AND WARRANTIES. The Company represents and warrants to
the Purchaser that on the date hereof:
          5.1 The Company is duly organized, validly existing, and in good
standing under the laws of its jurisdiction of incorporation and is duly
qualified and in good standing in every other jurisdiction where the nature of
its business or the location or ownership of its properties requires such
qualification and where the failure to be so qualified would reasonably be
expected to have a material adverse effect on the Company’s business,
operations, properties, assets or condition (financial or otherwise).
          5.2 The Company has the corporate power and authority to execute and
deliver this Agreement and the Convertible Note and to perform all of the
obligations hereunder, and all necessary corporate action has been taken to
execute and deliver this Agreement and the Convertible Note and to issue and
sell the Convertible Note hereunder.
          5.3 This Agreement and the Convertible Note constitute the legal,
valid, and binding obligations of the Company, enforceable against the Company
in accordance with their respective terms, subject to applicable bankruptcy,
insolvency, reorganization or similar laws generally affecting the enforcement
of the rights of creditors.
          5.4 The execution, delivery and performance by the Company of this
Agreement and the Convertible Note does not (i) violate any provisions of the
Company’s

7

--------------------------------------------------------------------------------

 

Certificate of Incorporation, as amended, bylaws, as amended, or any material
contract, agreement, law, regulation, order, decree or writ to which the Company
or any of its properties are subject or (ii) require the consent or approval of
any person, entity or authority, including, without limitation, any regulatory
authority or governmental body of the United States of America or any state
thereof or any political subdivision of any of the foregoing.
     6. REPRESENTATIONS AND WARRANTIES OF THE PURCHASER. The Purchaser
represents and warrants to the Company as follows:
          6.1 Investment Intent. The Purchaser understands that the Convertible
Note has not been registered under the Securities Act or any applicable state
securities law and is acquiring the Convertible Note as principal for its own
account for investment purposes only and not with a view to or for distributing
or reselling the Convertible Note, has no present intention of distributing the
Convertible Note and has no arrangement or understanding with any other persons
regarding the distribution of the Convertible Note. The Purchaser is acquiring
the Convertible Note hereunder in the ordinary course of its business. The
Purchaser does not have any agreement or understanding, directly or indirectly,
with any person to distribute the Convertible Note.
          6.2 Purchaser Status. At the time the Purchaser was offered the
Convertible Note, he was, and at the date hereof he is an “accredited investor”
as defined in Rule 501(a) under the Securities Act. The Purchaser (if not
already a registered broker-dealer under Section 15 of the Exchange Act) is not
required to be registered as a broker-dealer under Section 15 of the Exchange
Act.
          6.3 Experience of Purchaser. The Purchaser, either alone or together
with his representatives, has such knowledge, sophistication and experience in
business and financial matters so as to be capable of evaluating the merits and
risks of the prospective investment in the Convertible Note, and has so
evaluated the merits and risks of such investment. The Purchaser is able to bear
the economic risk of an investment in the Convertible Note and, at the present
time, is able to afford a complete loss of such investment.
          6.4 General Solicitation. The Purchaser is not purchasing the
Convertible Note as a result of any advertisement, article, notice or other
communication regarding the Convertible Note published in any newspaper,
magazine or similar media or broadcast over television or radio or presented at
any seminar or any other general solicitation or general advertisement.
          6.5 Certain Fees. No brokerage or finder’s fees or commissions are or
will be payable by the Purchaser to any broker, financial advisor or consultant,
finder, placement agent, investment banker, bank or other person with respect to
the transactions contemplated by this Agreement. The Company shall have no
obligation with respect to any fees or with respect to any claims made by or on
behalf of other persons for fees of a type contemplated in this Section 6.5 that
may be due in connection with the transactions contemplated by this Agreement.

8

--------------------------------------------------------------------------------

 

     7. AFFIRMATIVE COVENANTS. During the term of this Agreement and while the
Convertible Note remains outstanding, unless the Purchaser consents thereto in
writing:
          7.1 The Company shall maintain its corporate existence, business and
assets, keep its business and assets adequately insured and comply in all
material respects with all requirements of applicable law.
          7.2 The Company (a) shall provide the Purchaser at least 10 days prior
written notice of the Company’s intent to change its name or its mailing address
and (b) shall not change its type of organization or jurisdiction of
organization.
     8. NEGATIVE COVENANTS. So long as any principal and interest remains
outstanding under the Convertible Note, the Company shall not:
          8.1 Create, incur, assume, guaranty, become liable with respect to
(contingently or otherwise), or permit to be outstanding any indebtedness for
money borrowed (including, without limitation, any indebtedness evidenced by any
notes, instruments or agreements or in connection with any capitalized lease),
except for obligations under this Agreement and the Convertible Note;
          8.2 (i) Declare or pay any cash dividend, or make a distribution on,
repurchase, or redeem, any class of stock of the Company, other than pursuant to
repurchase obligations under existing employee stock purchase or option plans or
(ii) sell, lease, transfer or otherwise dispose of any material assets or
property of the Company; or
          8.3 Dissolve or liquidate.
     9. DEFAULTS. The occurrence of any one or more of the following events
shall constitute an “Event of Default”:
          9.1 The Company fails to pay any of the principal, interest or any
other amounts payable under this Agreement or the Convertible Note when and as
the same becomes due and payable;
          9.2 The Company files any petition or action for relief under any
bankruptcy, reorganization, insolvency or moratorium law or any other law for
the relief of, or relating to, Company, now or hereafter in effect, or seeks the
appointment of a custodian, receiver, trustee (or other similar official) of the
Company or all or any substantial portion of the Company’s assets, or makes any
assignment for the benefit of creditors or takes any action in furtherance of
any of the foregoing, or fails to generally pay its debts as they become due;
          9.3 An involuntary petition is filed, or any proceeding or case is
commenced, against the Company (unless such proceeding or case is dismissed or
discharged within ninety (90) days of the filing or commencement thereof) under
any bankruptcy, reorganization, arrangement, insolvency, adjustment of debt,
liquidation or moratorium statute now or hereafter in effect, or a custodian,
receiver, trustee, assignee for the benefit of creditors (or other similar
official) is applied for, appointed for the Company or to take possession,
custody or control of

9

--------------------------------------------------------------------------------

 

any property of the Company, or an order for relief is entered against the
Company in any of the foregoing; or
          9.4 Any representation or warranty made by the Company under this
Agreement shall have been false or misleading in any material respect when made
or deemed made.
     10. REMEDIES.
          10.1 Upon the occurrence and during the continuance of an Event of
Default hereunder, the Purchaser may, without notice or demand upon the Company,
do any or all of the following:
               (a) Declare all unpaid principal and accrued interest owing under
the Convertible Note held by him, and, in the case of an Event of Default
pursuant to Section 9.2 or 9.3 above, automatically, to be immediately due,
payable and collectible by him pursuant to applicable law;
               (b) Declare any and all unpaid principal and accrued interest due
under the Convertible Note held by him to thereafter bear interest at the
maximum rate set forth in Section 2.4 hereof;
               (c) Terminate any and all of his obligations to purchase any
additional Convertible Note hereunder; and
               (d) Exercise any and all rights and remedies he may have under
this Agreement, under the Convertible Note held by him or under applicable law.
          10.2 All of the foregoing rights and remedies shall be cumulative and
not exclusive. The failure to exercise all or any rights, remedies, powers or
privileges hereunder, under the Convertible Note or under applicable law, in any
instance shall not constitute a waiver thereof in that or any other instance.
     11. WAIVERS, AMENDMENTS AND OTHER PROVISIONS.
          11.1 Entire Agreement; Amendments; Invalidity. This Agreement and the
Convertible Note constitute the entire agreement and understanding of the
parties, and supersede and replace in their entirety any prior discussions or
agreements, all of which are merged herein and therein. None of the terms of
this Agreement or the Convertible Note may be amended or otherwise modified
except by an instrument executed by the Company and the Purchaser. If any term
of this Agreement or the Convertible Note shall be held to be invalid, illegal
or unenforceable, the validity of all other terms hereof shall in no way be
affected thereby, and this Agreement and the Convertible Note shall be construed
and be enforceable as if such invalid, illegal or unenforceable term had not
been included herein.
          11.2 Expenses. The Company agrees to and shall pay to the Purchaser on
demand, any and all expenses, including, without limitation, reasonable
attorney’s fees and disbursements, incurred or paid by the Purchaser in
connection with the collection on or

10

--------------------------------------------------------------------------------

 

enforcement of amounts outstanding hereunder, for protecting, preserving or
enforcing the Purchaser’s rights or remedies (including fees, costs and expenses
relating to any proceedings with respect to the bankruptcy, reorganization,
insolvency, readjustment of debt, dissolution or liquidation of the Company).
          11.3 Nonliability of the Purchaser; Several Obligation. The
relationship between the Company, on the one hand, and the Purchaser, on the
other hand, shall be solely that of Company and Purchaser. The Purchaser shall
have no fiduciary responsibilities to the Company as holder of the Convertible
Note.
          11.4 Governing Law: Consent to Jurisdiction. THIS AGREEMENT AND THE
CONVERTIBLE NOTE ARE INTENDED TO TAKE EFFECT AS A SEALED INSTRUMENT AND SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS (AND NOT THE LAWS OF
CONFLICT) OF THE COMMONWEALTH OF MASSACHUSETTS. THE COMPANY HEREBY IRREVOCABLY
SUBMITS TO THE JURISDICTION OF THE COURTS OF THE COMMONWEALTH OF MASSACHUSETTS
AND THE UNITED STATES DISTRICT COURT FOR THE COMMONWEALTH OF MASSACHUSETTS FOR
THE PURPOSE OF ANY SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF OR RELATING
TO THIS AGREEMENT AND THE CONVERTIBLE NOTE AND THE COMPANY HEREBY IRREVOCABLY
AGREES THAT ALL CLAIMS IN RESPECT OF SUCH ACTION OR PROCEEDING MAY BE HEARD AND
DETERMINED IN ANY SUCH COURT AND IRREVOCABLY WAIVES ANY OBJECTION IT MAY NOW OR
HEREAFTER HAVE AS TO THE VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN
ANY SUCH COURT OR THAT SUCH COURT IS AN INCONVENIENT FORUM. NOTHING HEREIN SHALL
LIMIT THE RIGHT OF THE PURCHASER TO BRING PROCEEDINGS AGAINST THE COMPANY IN THE
COURTS OF ANY OTHER JURISDICTION. ANY JUDICIAL PROCEEDING BY THE COMPANY AGAINST
THE PURCHASER OR ANY AFFILIATE OF THE PURCHASER UNDER OR INVOLVING, DIRECTLY OR
INDIRECTLY, ANY MATTER IN ANY WAY ARISING OUT OF, RELATED TO, OR CONNECTED WITH
THIS AGREEMENT OR THE CONVERTIBLE NOTE SHALL BE BROUGHT ONLY IN A COURT IN THE
COMMONWEALTH OF MASSACHUSETTS.
          11.5 Waiver of Jury Trial and Certain Damages. EACH OF THE COMPANY AND
THE PURCHASER WAIVES ITS RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR
CLAIM ARISING OUT OF ANY DISPUTE IN CONNECTION WITH THIS AGREEMENT OR ANY
CONVERTIBLE NOTE, ANY RIGHTS OR OBLIGATIONS HEREUNDER OR THEREUNDER OR THE
PERFORMANCE OF ANY SUCH RIGHTS OR OBLIGATIONS. Except as prohibited by law, the
Company waives any right which it may have to claim or recover in any litigation
referred to in the preceding sentence any special, exemplary, punitive or
consequential damages or any damages other than, or in addition to, actual
damages. The Company (i) certifies that neither the Purchaser nor any
representative, agent or attorney of the Purchaser has represented, expressly or
otherwise, that the Purchaser would not, in the event of litigation, seek to
enforce the foregoing waivers and (ii) acknowledges that, in entering into this
Agreement and the Convertible Note, the Purchaser is relying upon, among other
things, the foregoing waivers and certifications.

11

--------------------------------------------------------------------------------

 

          11.6 Successors and Assigns. This Agreement and the other Loan
Documents and all obligations of the Company hereunder and thereunder shall be
binding upon the successors and assigns of the Company, and shall, together with
the rights and remedies of the Purchaser hereunder, inure to the benefit of the
Purchaser, any future holder of this Agreement or any other Loan Document and
their respective successors and assigns, provided, however, the Company may not
transfer or assign its rights or obligations hereunder or thereunder without the
express written consent of the Purchaser, and any purported transfer or
assignment by the Company without the approval of the Purchaser shall be null
and void. The Purchaser may assign, transfer, participate or endorse his rights
under this Agreement or any of the other Loan Documents without the consent or
approval of the Company, and all such rights shall inure to the Purchaser’s
successors and assigns; provided, that such transferee agrees in writing to be
bound by all of the terms of this Agreement. No sales of participations, other
sales, assignments, transfers, endorsements or other dispositions of any rights
hereunder or thereunder or any portion hereof or thereof or interest herein or
therein shall in any manner affect the obligations of the Company under this
Agreement or the other Loan Documents. The Company agrees that in connection
with any such assignment, to execute and deliver such additional documents or
agreements, including, without limitation, a new Convertible Note, as may be
reasonably requested.
          11.7 Counterparts. This Agreement may be executed in any number of
separate counterparts, all of which, when taken together, shall constitute one
and the same instrument, notwithstanding the fact that all parties did not sign
the same counterpart.
          11.8 No Reliance. The Purchaser hereby acknowledges (i) that Wilmer
Cutler Pickering Hale and Dorr LLP has served as counsel solely to the Company
in connection with entering into this Agreement and the Convertible Note and the
transactions contemplated hereby and thereby and not as counsel to the
Purchaser, and (ii) that the Purchaser (a) has sought the advice of his own
legal counsel and has not relied upon Wilmer Cutler Pickering Hale and Dorr LLP,
(b) has had an opportunity to fully discuss and review the terms of this
Agreement and the Convertible Note and the transactions contemplated hereby and
thereby with the Purchaser’s counsel, and (c) understands the contents herein
and freely and voluntarily assents to all of the terms and conditions hereof and
the transactions contemplated hereby.
[Remainder of Page Intentionally Left Blank]

12

--------------------------------------------------------------------------------

 

     IN WITNESS WHEREOF, this Agreement has been duly executed as an instrument
under seal as of the date first set forth above.

            COMPANY:

ALSERES PHARMACEUTICALS, INC.
      By:   Kenneth L. Rice, Jr.       Printed Name:   Kenneth L. Rice, Jr.     
  Title:  
Address: EVP & CFO
85 Main Street
Hopkinton, Massachusetts 01748       

          PURCHASER:    
 
        ROBERT GIPSON    
 
       
Signature:
  Robert L. Gipson
 
   
Address:
  c/o Ingalls & Snyder LLC    
 
   61 Broadway, NY, NY 10006    

13

--------------------------------------------------------------------------------

 

EXHIBIT A
THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF
THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”), NOR UNDER ANY STATE SECURITIES LAWS AND MAY NOT BE PLEDGED, SOLD,
ASSIGNED OR OTHERWISE TRANSFERRED UNTIL A (1) REGISTRATION STATEMENT UNDER THE
ACT AND ANY APPLICABLE STATE SECURITIES LAW HAS BECOME EFFECTIVE WITH RESPECT
THERETO, OR (2) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL TO THE COMPANY
TO THE EFFECT THAT REGISTRATION UNDER THE ACT OR APPLICABLE STATE SECURITIES LAW
IS NOT REQUIRED IN CONNECTION WITH THE PROPOSED TRANSFER.
CONVERTIBLE PROMISSORY NOTE

       $[                    ]    , 2008

Hopkinton, Massachusetts
     FOR VALUE RECEIVED, on the Maturity Date, Alseres Pharmaceuticals, Inc., a
Delaware corporation having a principal place of business at 85 Main Street,
Hopkinton, Massachusetts 01748 (the “Company”), hereby unconditionally promises
to pay to [Purchaser] (the “Purchaser”), or order, at [                    ], or
such other place as Purchaser or any holder hereof may from time to time
designate, the principal sum of [                    ] Dollars
[($                    )], in United States Dollars and in immediately available
funds as provided in the Convertible Promissory Note Purchase Agreement of even
date between the Company and the Purchaser (the “Agreement”), together with
interest on the unpaid principal amount hereof from time to time outstanding at
the rate and on the dates set forth in the Agreement. This Convertible
Promissory Note may be one of a series of Convertible Promissory Notes issued
pursuant to the Agreement and each such Convertible Promissory Note shall rank
pari passu in right of repayment to such other Convertible Promissory Note.
     This Convertible Promissory Note is issued pursuant to, and is entitled to
the benefits of, the Agreement, as it may be amended from time to time.
Reference is hereby made thereto for a statement of the terms and conditions
under which this Convertible Promissory Note may be converted, prepaid or its
maturity date accelerated. This Convertible Promissory Note is convertible at
the election of the Purchaser pursuant to Sections 4.1 and 4.2 of the Agreement.
Capitalized terms used herein and not otherwise defined herein are used with the
meanings attributed to them in the Agreement.
     No delay or omission on the part of the Purchaser in exercising any right
hereunder shall operate as a waiver of such right or of any other right of
Purchaser, nor shall any delay, omission or waiver on any one occasion be deemed
a bar to or waiver of the same or any other right on any future occasion. The
Company and every endorser or guarantor of this Convertible Promissory Note
regardless of the time, order or place of signing waives presentment, demand,
protest and notices of every kind and assents to any extension or postponement
of the time of

 

--------------------------------------------------------------------------------

 

payment or any other indulgence, and to the addition or release of any other
party or person primarily or secondarily liable.
     The terms and provisions of this Convertible Promissory Note may be
excluded, modified, or amended only as set forth in the Agreement. This
Convertible Promissory Note shall be binding upon the successors and assigns of
the Company and inure to the benefit of Purchaser and its successors, endorsees
and assigns as set forth in the Agreement. If any term or provision of this
Convertible Promissory Note shall be held to be invalid or unenforceable, in
whole or in part in any jurisdiction, then such invalidity or unenforceability
shall only effect such term or provision, and shall not effect such term or
provision in any other jurisdiction or any other term or provision of this
Convertible Promissory Note.
     The Company hereby waives its right to a jury trial with respect to any
action or claim arising out of any dispute in connection with this Convertible
Promissory Note or any of the other Loan Documents, any rights or obligations
hereunder or thereunder or the performance of such rights and obligations.
     All rights and obligations hereunder shall be governed by the laws of the
Commonwealth of Massachusetts (without giving effect to principles of conflicts
or choice of laws) and this Convertible Promissory Note shall be deemed to be
made under seal.

                  Alseres Pharmaceuticals, Inc.    
 
           
 
  By  
 
   
 
   
 
   
 
           
 
  Name:        
 
           
 
           
 
  Title:        
 
           

2